📰 Evofem Bioscience News
Page 3 - Evofem Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Evofem Bioscience. Real-time updates on events, politics, business and more.
June 4, 2022
Equities analysts predict that Evofem Biosciences, Inc. (NASDAQ:EVFM – Get Rating) will report sales of $6.65 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Evofem Biosciences’ earnings. The lowest sales estimate is $5.50 million and the highest is $8.56 million. Evofem Biosciences reported sales of $1.86 million in the […]
June 2, 2022
/PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced that the U.S. Food and Drug Administration (FDA) has formally extended the...
May 20, 2022
/PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced the pricing of its previously announced underwritten public offering of...
May 19, 2022
/PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced that it intends to offer and sell shares of its common stock (or pre-funded...
May 19, 2022
/PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced that it intends to offer and sell shares of its common stock (or pre-funded...
May 6, 2022
/PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced that new data from the Phase 3 AMPOWER clinical trial of Phexxi® (lactic acid, citric...
May 5, 2022
Evofem Biosciences, Inc. (NASDAQ:NASDAQ:EVFM) Q1 2022 Results Conference Call May 4, 2022 4:30 PM ET Company Participants Amy Raskopf - Vice President-Investor Relations Saundra Pelletier -...
May 5, 2022
/PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) (the "Company") today announced that the Board and stockholders of the Company approved a 1-for-15...
April 27, 2022
/PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that it has entered into a new agreement with VitaCare Prescription Services, a...
April 26, 2022
/PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it will present new data from the Phase 3 AMPOWER Clinical Trial at the 2022 American...